SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher ® Prostate RP genomic classifier is uniquely recommended in the 2022 National ...
“This study suggests that using the Decipher Prostate test to more precisely determine prognosis and risk for men with intermediate-risk prostate cancer – and thereby potentially optimizing individual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback